PharmaSens adds two to board
By HME News Staff
Updated 10:43 AM CST, Wed November 6, 2024
BIEL/BIENNE, Switzerland – PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors. The Swiss company is developing an insulin delivery platform and is working to bring to patients the first all-in-one wearable patch device integrating both insulin delivery and continuous glucose sensing. "Welcoming Dr. Bob Gabbay and James Peterson to our board is a great honor and represents a significant milestone for PharmaSens as the company delves more deeply into the clinical research phase and looks to develop internationally," said Jean Patricot, chairman of the PharmaSens board. "Their expertise will strengthen our efforts to simplify diabetes management and expand access to insulin pump therapy for more people with diabetes." Gabbay recently stepped down as chief scientific and medical officer of the American Diabetes Association, where he led ADA’s efforts to drive discovery within the world of diabetes research, care and prevention. Peterson has extensive executive leadership experience in company growth, mergers and acquisitions, corporate fundraising, venture building, and the development of new businesses and technology. He was previously president and CEO of global health care company Haemonetics.
Comments